ODYSSEY GROUP INTL INC - ODYY STOCK NEWS

Odyssey Health, Inc. (OTC: ODYY) has successfully completed safety measures for its Phase I Multi-Day Ascending Dosing (MAD) clinical trial of PRV-002, a novel drug designed to treat concussions. The first cohort involved eight healthy volunteers and reported no severe adverse events, indicating that the treatment was well-tolerated. The drug's pharmacokinetics demonstrated a direct linear relationship between dosing and blood levels, with significantly lower plasma levels noted for intranasal administration. The company is moving forward with the second cohort of the trial.

Odyssey Health (OTC: ODYY) announced positive safety results from Cohort I of its Phase I clinical trial for PRV-002, a drug addressing concussion treatment. Administered to eight healthy volunteers over five consecutive days, PRV-002 was found to be safe and well tolerated, with no severe adverse events reported. Conducted by Avance Clinical Pty Ltd, the trial aims to evaluate PRV-002's efficacy as a potential solution to a significant medical need in concussion management. The ongoing Phase I trial will include a total of 16 healthy subjects, with additional results to be reported.

Odyssey Health (OTC Pink: ODYY) is set to appear on Bloomberg TV's RedChip Money Report on July 16, 2022. The interview features spokesperson Brett Favre, discussing his personal concussion experiences and Odyssey's concussion treatment potential. The show reaches 73 million households, offering significant exposure for Odyssey. The company focuses on developing innovative medical solutions with a mission to enhance lives and ensure substantial returns for shareholders.

Odyssey Health (OTC Pink: ODYY) has successfully completed all three cohorts of its Phase I Single Ascending Dosing clinical trial for PRV-002, a novel concussion treatment. The drug was safe and well tolerated, showing promising pharmacokinetic results. The company plans to proceed with the Multiple Ascending Dosing phase and aims to meet with the FDA to discuss findings. The market for concussion treatments is projected to grow from $6.9 billion in 2020 to $8.9 billion by 2027, highlighting the potential impact of PRV-002 in addressing an unmet medical need.

Odyssey Health, Inc. (OTC Pink: ODYY) announced favorable safety results from Cohort II of its Phase I clinical trial for PRV-002, a novel drug to treat concussions. Conducted at Nucleus Network, this cohort included six healthy volunteers with no severe adverse events. All vital signs and blood tests remained normal, leading to unanimous approval for the next cohort with increased dosage. CEO Michael Redmond highlighted ongoing discussions for Phase II/III trials. The global concussion treatment market is projected to grow from $6.9 billion in 2020 to $8.9 billion by 2027.

Odyssey Health, Inc. (OTC Pink: ODYY) will be featured in a C-Level interview on The RedChip Money Report®, airing June 11 at 7 p.m. ET on Bloomberg TV, reaching 73 million homes in the U.S. CEO Michael Redmond discusses Odyssey's innovative concussion treatment and other medical solutions, targeting a $400 billion market. The company focuses on unmet medical needs with products like CardioMap® and Save-A-Life®, aiming to set industry standards. The interview promises insights on human trials and strategic objectives.

Odyssey Health, Inc. (OTC Pink: ODYY) announced positive safety results from Cohort I of their Phase I clinical trial for PRV-002, a novel drug aimed at treating concussions. Conducted at Nucleus Network, the trial involved eight healthy subjects who reported no severe adverse effects, indicating that PRV-002 was well-tolerated. Vital signs and lab results remained normal. With a global concussion treatment market valued at $6.9 billion in 2020, Odyssey is optimistic about the drug's potential efficacy in future trials, as stated by executives.

Odyssey Health, Inc. (OTC Pink: ODYY) announced positive outcomes from the initial group of patients in their Phase I clinical trial for PRV-002, a novel treatment for concussions. The drug has been shown to be safe and well-tolerated in five healthy subjects, with no serious adverse events reported. Every year, over three million concussions occur in the U.S., presenting a significant unmet medical need. The company aims to complete the trial and present findings to the FDA, with plans for a subsequent Phase II trial focused on military applications.